Initially Neutral on the company, Warburg Research s analyst Oliver Schwarz maintained his recommendation. The target price continues to be set at EUR 51.
In his latest research note, analyst Andreas Wolf confirms his positive recommendation. The broker Warburg Research is keeping its Buy rating. The target price continues to be set at EUR 59.
Unclear prospects continue to dampen Evotec s share price on Wednesday after the latest figures. The pharmaceutical drug researcher and developer recorded a weaker start to the year, but above all the.
In a research note, Warburg Research analyst Malte Schaumann has maintained his recommendation on the stock with a Buy rating. The target price is unchanged and still at EUR 27.